

**DRUG DISCOVERY TODAY****Editorial****Editor:** Steve Carney**Assistant Editor:** Karen Manser**Content Development Managers:** Sandra Korver  
and Jasmin Bakker**Journal Manager:** Basil Nyaku**Publisher:** Jaap van Harten**Editorial Enquiries:***Drug Discovery Today*

Elsevier

32 Jamestown Road, London, NW1 7BY, UK

Tel: +44 (0)20 7424 4200

Fax: +44 (0)1865 853067

Email: ddt@drugdiscoverytoday.com

**ADVISORY EDITORIAL BOARD****Jürgen Bajorath** *University of Bonn, Germany***Walter Blackstock** *Experimental Therapeutics  
Centre, Singapore***David Brayden** *University College Dublin, Ireland***Paul Caron** *Vertex Pharmaceuticals, USA***David Cavalla** *Arachnova, UK***David Clark** *Argenta Discovery, UK***Dalia Cohen** *Rosetta Genomics, USA***Donald Daley** *Argenta Discovery, UK***Sean Ekins** *ACT LLC and Collaborations in  
Chemistry, USA***Hans-Peter Fischer** *GeneData, Switzerland***Peter Ghazal** *University of Edinburgh, UK***Christopher M. Hill** *Organon, UK***Nick Hird** *Takeda Chemical Industries, Japan***Enoch Huang** *Pfizer, USA***Thomas Joos** *University of Tuebingen, Germany***Vincent H.L. Lee** *Chinese University of Hong Kong,  
Hong Kong***David Lewin** *Yale University, USA***Christopher A. Lipinski** *Melior Discovery, USA***Lorenz Mayr** *Novartis, Switzerland***Nick Meanwell** *Bristol-Myers Squibb, USA***BK Muralidhara** *Pfizer Global Biologics, St. Louis,  
USA***Mark Murcko** *Vertex Pharmaceuticals, USA***Fajun Nan** *Shanghai Institute of Materia Medica,  
China***Pradeep Nathan** *Experimental Medicine, GSK and  
University of Cambridge***Gitte Neubauer** *Cellzome, Germany***Eric Neumann** *Teranode, USA***Tim Peakman** *UK Biobank, UK***Norton Peet** *Aurigene, USA***Manuel Peitsch** *Novartis, Switzerland***Kurt Rasmussen** *Eli Lilly and Co. Ltd., USA***Janice Reichert** *Tufts Center for the Study of Drug  
Development, USA***John Reidhaar-Olson** *Hoffmann–La Roche, USA***Mike Romanos** *GlaxoSmithKline, UK***Raymond C. Rowe** *Intelligensys, UK***Andreas Russ** *University of Oxford, UK***Esther Schmid** *Pfizer, UK***Jonathan Sheldon** *Inforsense, UK***Michael Snyder** *Yale University, USA***Susie Stephens** *Eli Lilly and Co. Ltd., USA***Robert Strausberg** *The J. Craig Venter Institute,  
USA***Donny Strosberg** *Scripps Florida, USA***Yuichi Sugiyama** *University of Tokyo, Japan***David Szymkowski** *Xencor, USA***Nick Terrett** *Ensemble Discovery, USA***Vladimir Torchilin** *Northeastern University, Boston,  
USA***Mark Whittaker** *Evotec OAI, UK***Hans Winkler** *Johnson and Johnson, Belgium***Limsoon Wong** *Laboratories for Information  
Technology (LIT), Singapore***X.F. Steven Zheng** *Robert Wood Johnson Medical  
School, USA*DRUG DISCOVERY  
TODAY

## EDITORIAL

**183 Pathways and targets—opposite approaches to success?***Keith Blundy*

## PERSPECTIVE

## FEATURE

**185 Collaborative approaches to anticancer drug discovery and development: a Cancer Research UK perspective***Robert J. Williams, Ian Walker and Andrew K. Takle***188 Exploiting genetic complexity in cancer to improve therapeutic strategies***Mathew J. Garnett and Ultan McDermott***277 DIARY**

## FORTHCOMING ARTICLES

**Can we discover pharmacological promiscuity early in the drug discovery process?***By Jens-Uwe Peters, Jérôme Hert, Caterina Bissantz, Alexander Hillebrecht, Grégori Gerebtzoff, Stefanie Bendels, Fabien Tillier, Jacques Migeon, Holger Fischer, Wolfgang Guba and Manfred Kansy***Stem cell technology for drug discovery and development***By Lilian A Hook***Computational models for predicting substrates or inhibitors of P-glycoprotein***By Lei Chen, Youyong Li, Huidong Yu, Liling Zhang and Tingjun Hou***Amino acid–anticodon binding specificity: rationale for a new class of therapeutic agent***By Marvin S. Melzer*